Tagged with Strategy,

Saudi Arabia Boston Scientific’s general manager for Saudi Arabia, Basel Al-Qahtani, highlights the company’s bet on the country – including the move to a direct presence and the signing of a memorandum of understanding to establish regional headquarters in Riyadh. In addition, he explains the public-private sector dynamics as it relates to…

Denmark Europe lags behind the US in terms of biotech success stories, but one company bucking that trend is Denmark-headquartered Genmab, with a market cap of over USD 25 billion. Dual-listed on the Copenhagen stock exchange and on NASDAQ in the US, there are five products based on Genmab science on…

Denmark Speaking exclusively to PharmaBoardroom, Jan van de Winkel highlights the tremendous progress that European biotech success story Genmab has made over the past six years, how its partnership model is evolving, Denmark’s continuing relevance to the company, and Genmab’s value proposition for the next generation of talent.   Genmab has…

Saudi Arabia Medtronic’s country director for Saudi Arabia, Mohammed El Ansari, comments on the implications of the company’s decision to move to a direct presence in the Kingdom, positioning the affiliate as a career launchpad for local talent, the local manufacturing of ventilators, and why Medtronic considers Saudi Arabia a priority market.…

Saudi Arabia Ipsen’s general manager for Middle East and Africa (MEA), Khaled Elrefae, highlights the French firm’s expanding footprint in the region, the fundamentals that make MEA a growth driver for Ipsen, and the opportunities for further growth from its oncology, rare disease and neuroscience portfolios. In addition, Elrefae discusses the changing…

Saudi Arabia After almost two decades with MSD, Ashraf Mallak, managing director for the company in the GCC region, dives into the often-overlooked healthcare capabilities of the Gulf countries, including the fact that certain products approved by the US FDA can sometimes be available in the region in as little as one…

UK The latest news from UK pharma, including AstraZeneca’s decision to create a dedicated business unit for its COVID-19 vaccines, GSK’s raised profits forecast, and CDMO Almac’s move to create over 1,000 new jobs at its facilities in Northern Ireland over the next three years.   AstraZeneca to create dedicated Covid…

Saudi Arabia Medochemie’s Yasser Sabra gives a fascinating insight into the branded generic and value added medicine field today, including why the COVID-19 pandemic could lead to a reappraisal of medicine repurposing. Sabra also touches on the firm’s operations in the Middle East’s biggest market of Saudi Arabia, explaining why the Saudi…

Denmark Kasper Bødker Mejlvang oversees Novo Nordisk’s operations in its historic home market of Denmark, as well as Iceland. Here, Bødker Mejlvang explains his strategy for steering the Danish affiliate through the COVID-19 pandemic, the evolving access landscape for the company’s next-generation diabetes and obesity treatments, and why Denmark – despite…

Turkey Okan Güner of Viatris Turkey introduces the company’s sizeable footprint in the country, including local manufacturing and explains the challenges of executing an integration of two companies during the COVID-19 pandemic. Güner outlines Viatris’ role within Turkey’s Vision 2023, the opportunities for their biosimilars pipeline, and their portfolio’s role in…

Saudi Arabia Recently appointed CEO of Saudi Chemical Company Holding’s Pharma Sector, Ismail Shehada is today drawing on 20+ years of Big Pharma experience to drive SCCH’s growing life sciences footprint in alignment with the Kingdom of Saudi Arabia’s Vision 2030 healthcare transformation. Shehada explains how SCCH is moving into third-party logistics…

Switzerland Barbara Fritsche-Surchat outlines Servier’s historic commitment to Switzerland, how the French mid-cap’s global oncology pivot is translating into its Swiss operations, and comments on the evolution of pharma salesforces post-pandemic.   Over the years, we have developed a real expertise, predominantly in the cardiovascular field, but we will leverage this…